Regeneron Strikes A CHORD With Deafness Gene Therapy

A very early success with a gene therapy for a rare form of deafness puts Regeneron ahead of Lilly and Sensorion.

There are no approved pharmacological therapies for congenital hearing loss and this situation is unlikely to change any time soon. Still, a glimmer of hope has been provided with signs of hearing improvement in a single patient with profound genetic deafness after treatment with Regeneron Pharmaceuticals, Inc.’s gene therapy, DB-OTO.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

29 Apr 2025

• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

14 Apr 2025

• By Alaric DeArment

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

10 Apr 2025

• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

What Is Fuelling Cell And Gene Therapies In India?

07 Apr 2025

• By Vibha Ravi

Bharat Biotech is the latest entrant in India’s cell and gene therapy space, joining majors like Intas Pharma, Sun Pharma, Cipla and Dr. Reddy’s. An indigenously developed CAR-T cell therapy launched last year, what is driving growing interest and success in cell and gene therapies?